Regulatory Capacity Building Workshop: Vaccine Clinical Trial Review from Ebola to HIV GERMAN CENTRE FOR INFECTION RESEARCH (DZIF)
|
|
- Osborne Lynch
- 6 years ago
- Views:
Transcription
1 Regulatory Capacity Building Workshop: Vaccine Clinical Trial Review from Ebola to HIV Kigali, Rwanda March 2015 GERMAN CENTRE FOR INFECTION RESEARCH (DZIF) Christoph Conrad Paul-Ehrlich-Institut Paul-Ehrlich-Strasse Langen GERMANY +49 (0) (0) Homepage:
2 German Centers for Translational Research (DZG) German Center for Infection Research (DZIF) German Center for Cardiovascular Research (DZHK) German Center for Lung Research (DZL) German Consortium for Translational Cancer Research (DZK) German Center for Diabetes Research (DZD) German Center for Neurodegenerative Diseases (DZNE) 2 German Centers for Translational Research
3 Decentralized Structure of DZG Cancer Heart Lung Neuro Diabetes Infection 3 German Centers for Translational Research
4 German Center for Infection Research (DZIF) 7 Partner Sites 32 Academic Institutions 4 German Center for Infection Research
5 Mission and Objectives Integrate the existing, but fragmented strength in infection research into a National Center for Translational Infection Research in Germany Close the gap in the translational chain in infection research Establish a product development structure Develop new approaches for the diagnosis, prevention and therapy of important infectious disease challenges Establish a clinical trial structure in DZIF Support career development in infection research and infectious diseases Establish DZIF as a new National Center for Infection Research 5 Mission and Objectives
6 DZIF Support of TTUs: Infrastructures Grand Challenges Emerging Global Immunocompromised Host Therapy-resistant 5.1 TTU Emerging 5.4 TTU HIV 5.7 TTU of the Immunocompromised Host 5.8 TTU Healthcareassociated 6.1 DZIF Product Development Unit 5.2 TTU Tuberculosis 5.5 TTU Hepatitis 5.9 TTU Novel Antiinfectives 6.6 DZIF Bioinformatics 6.2 DZIF Clinical Trial Unit 6.3 DZIF African Partner Sites 5.3 TTU Malaria 6.7 DZIF Academy 5.6 TTU Gastrointestinal 6.4 DZIF Biobanking 6.5 DZIF Natural Compound Library Thematic Translational Units Translational Infrastructures 6 Infrastructures
7 The Translational Mission DZIF-Product Development Unit (DZIF-PDU) Academia Translational GAP Pharmaceutical/ Biotech Industry DZIF-Product Development Unit (PDU) Translational Project Management Office Office for Scientific and Regulatory Advice (PEI) DZIF Infrastructure Clinical Trial Unit Discovery Preclinical Development Clinical Development Market 7 The Translational Mission
8 DZIF African Partner Sites Coordinators Jürgen May, Hamburg-Lübeck-Borstel (co-representing TTU Malaria) Christian Drosten, Bonn-Köln (co-representing TTU EI) Site representatives Peter Kremsner, Tübingen (representing TTU Malaria) Michael Hoelscher, München (co-representing TTU Tb) Rainer Sauerborn, Heidelberg Achim Hörauf, Bonn-Köln (co-representing TTU Novel Antiinfectives) Focus Sites Kumasi/Ghana Ellis Owusu-Dabo, Deputy Director, Kumasi Centre for Collaborative Research, Kumasi, Ghana Lambaréné/ Gabon A. Adegnika, Deputy Director, Medical Research Unit, Albert Schweizer Hospital Lambaréné, Gabon Mbeya/ Tanzania L. Maboko, Co- Director, Mbeya Medical Research Programme, Tanzania Nouna/ Burkina Faso A. Sié, Centre de Recherche en Sante de Nouna, Burkina Faso Partner Sites Hamburg-Lübeck- Borstel Bonn-Köln Tübingen München J. May B. Kreuels R. Krumkamp T. Tamminga C. Drosten A. Hörauf P. Kremsner B. Mordmüller M. Hoelscher N. Heinrich A. Kroidl E. Saathoff Heidelberg R. Sauerborn, T. Junghanss
9 The Translational Mission: From Bench to Bedside 9 The Translational Mission
10 Perspectives 2015 TTUs matured into centres of excellence New DZIF faculty recruited, infrastructures established and operating One to two anti-infectives / vaccines processed through preclinical studies and clinical phase I/II trials until 2015 Strategic Alliances with Industry, national and international Institutions DZIF will become a true National Center for Translational Infection Research in Germany 10 Perspectives 2015
11 Thank you for your attention!
Data Warehouse Systems at the German Centers for Health Research (DZG)
Data Warehouse Systems at the German Centers for Health Research (DZG) Roland Eils 26.10.16 Roland Eils The German Centers for Health Research è Fighting major disease challenges è Translational Research,
More informationEDCTP perspective on biopreparedness and related capacity development in Africa
EDCTP perspective on biopreparedness and related capacity development in Africa Consultation workshop on Preparedness for emerging diseases Dr. Michael Makanga EDCTP Executive Director. 29 September 2016
More informationInnovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
More informationOPPORTUNITIES AND CHALLENGES FOR REGULATORY AUTHORIZATION AND OVERSIGHT OF CLINICAL TRIALS IN RESOURCE-LIMITED SETTINGS
Regulatory Capacity Building Workshop: Vaccine Clinical Trial Review from Ebola to HIV, 18-20 March, 2015, Kigali, Rwanda OPPORTUNITIES AND CHALLENGES FOR REGULATORY AUTHORIZATION AND OVERSIGHT OF CLINICAL
More informationThe Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels
The Innovative Medicines Initiative Europe s partnership for health Tek-Ang LIM, 20 June 2018, Brussels 10 YEARS OF LIGHTING THE WAY IMI Why Europe s partnership for health? Because despite decades of
More informationThe German Network Against Neglected Tropical Diseases (DNTDs)
The German Network Against Neglected Tropical Diseases (DNTDs) 1 NTD Networks International 2 Background International 2011 Roadmap of the World Health Organization Priorization of 17 out of more than
More informationNew Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
More information2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships
2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships Call Identifier: TMA2017IF The purpose of this Call for Proposals is to provide funding towards actions that aim to support
More informationTranslational Medicine From Discovery to Health
Translational Medicine From Discovery to Health Jamal A. Ibdah, MD, PhD Sr. Associate Dean & Director, MU Institute for Clinical and Translational Science Translational Medicine Translational Medicine
More informationInnovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
More information+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA
At the Center for Infectious Disease Research, we use systems biology approaches and cutting-edge technologies to accelerate the development of life-saving drugs, diagnostics and treatments for the world
More informationCollaborations between pharma industry and academia as drivers for innovations
Collaborations between pharma industry and academia as drivers for innovations Dr. Monika Lessl Director Alliance Management Global Drug Discovery Bayer Schering Pharma Berlin, Germany Deutsch - Brasilianische
More informationThe Innovative Medicines Initiative Socio-economic impacts
The Innovative Medicines Initiative Socio-economic impacts Pierre Meulien, IMI Executive Director European Innovation Summit European Parliament 08.12.2015 Closed & open innovation Filing Approval HTA
More informationFrom IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014
From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the
More informationVaccine Clinical Trials
Vaccine Clinical Trials Simon Agwale, PhD CEO Innovative Biotech Ltd, Keffi, Nigeria Chair, Developing countries Coordinating Committee (DCCC)-European and Developing Countries Clinical Trials Partnership
More informationCritical Path to TB Drug Regimens Role in Facilitating TB Drug Development
Critical Path to TB Drug Regimens Role in Facilitating TB Drug Development Debra Hanna, Executive Director, Critical Path to TB Drug Regimens 11 September 2017 CPTR S MISSION AND FOCUS Mission: The Critical
More informationBIO-INNOVATION FOR HEALTH: SOUTH AFRICA
BIO-INNOVATION FOR HEALTH: SOUTH AFRICA SA s Burden of Disease SA MRC is committed to addressing the burden of disease that impacts health Cause of death Deaths % HIV/AIDS 180,870 29.4 Hypertensive heart
More informationOpportunities for industry/smes in EU-funded health research
Opportunities for industry/smes in EU-funded health research Stéphane Hogan, M.Sc, MBA Head of Unit Applied Genomics and Biotechnology for Health DG Research - European Commission 1 Paris, 31 May 2005
More informationCIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator
FP7 Health Partnering event 10 June 2011, Brussels International session CIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator Translational Research CIBIR:
More informationEU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
More informationPartnering & Networks
Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith
More informationDuncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline
R&D Strategy Bridging g the academia-industry industry yg gap Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline GSK at a glance Who we are We are a science-led global healthcare
More informationIMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
More informationEBOLA - HANDS ON WORKSHOP
ICPIC Pre-meeting workshop June 16, 2015 (10:00-16:50) EBOLA - HANDS ON WORKSHOP 10:00-12:45 Field experiences with Ebola virus disease in West Africa Moderators: Prof. Benedetta Allegranzi, Prof. Babacar
More informationA gateway to academic excellence for Biotech and Pharma
A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging
More informationNobel Prize Award to Paul Ehrlich. Nürnberg, Germany. October 3-5, 2008
Nürnberg, Germany October 3-5, 2008 Program Welcome to Nürnberg, We are pleased that you took the occasion of the celebration of the 100 th Anniversary of the Nobel Prize awarded to Paul Ehrlich to come
More informationExplaining EDCTP2 and its perspective on Capacity Building for PV of products used in managing PRDs
Explaining EDCTP2 and its perspective on Capacity Building for PV of products used in managing PRDs 16 th Annual meeting of the International Society of Pharmacovigilance Jean Marie Vianney Habarugira,
More informationINSTITUT PASTEUR INSTITUT PASTEUR IS A PRIVATE, NON PROFIT, INSTITUTE DEDICATED TO RESEARCH & PUBLIC HEALTH
www.pasteur.fr INSTITUT PASTEUR INSTITUT PASTEUR IS A PRIVATE, NON PROFIT, INSTITUTE DEDICATED TO RESEARCH & PUBLIC HEALTH INSTITUT PASTEUR Created in 1887 by Louis Pasteur 2,700 people working in Paris
More informationThe Seventh Framework Programme ( )
The Seventh Framework Programme (2007-2013) Opportunities for Cardiovascular Research 1 Octavi Quintana Trias, MD, MPH Director Health DG Research - European Commission Octavi.Quintana-Trias@ec.europa.eu
More informationResearch and development case study. Human health research
Research and development case study Human health research November 2017 Introduction This case study on human health research is one of a series that we have developed to support and complement our published
More informationPublic private partnerships
THE INTERNATIONAL CONFERENCE ON (RE-)EMERGING INFECTIOUS DISEASES 14 March 2018 in Addis Ababa, Ethiopia Public private partnerships Engaging the private research sector to scale up infectious diseases
More informationRegulatory Support to EU Research
Regulatory Support to EU Research OPEN INFO DAY Horizon 2020 'Health, demographic change and wellbeing Friday, 8 December 2017 Brussels Presented by Marisa Papaluca Senior Scientific Advisor, Scientific
More informationA European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director ITMAT 2010, 27 October 2010 EFPIA Member Companies Participating companies (September 2010):! Innovative
More informationEMA s role & responsibility for the development of modern/advanced therapies
EMA s role & responsibility for the development of modern/advanced therapies Agenda Current regulatory picture Overall Regulatory framework New Committee at EMA Current Activities & Challenges Egbert Flory
More informationEMBARGOED UNTIL 7:38 AM October 31, 2016
EMBARGOED UNTIL 7:38 AM October 31, 2016 Media Contacts: Memorial Sloan Kettering The Rockefeller University Weill Cornell Medicine Cancer Center Katherine Fenz Jennifer Gundersen Caitlin Hool 212-327-7913
More informationNIH-RAID: A ROADMAP Program
NIH-RAID: A ROADMAP Program (Rapid Access to Interventional Development} A Program designed to facilitate the development of new therapeutics The NIH-RAID Pilot Program is intended to reduce some of the
More informationCollaborative clinical research between EU & sub-saharan Africa
Collaborative clinical research between EU & sub-saharan Africa European & Developing Countries Clinical Trials Partnership Dr Monique Surette, EDCTP Senior Project Officer EC Open Info Day - Horizon 2020
More informationList of E-journals Subscribed for the year 2016 (January to December) Pharmacy Faculty Sl. No.
Faculty 1 Adolescent Psychiatry Psychiatry 2 Anti Cancer Agents in Medicinal / Pharma & Quality 3 Anti-Infective Agents Pharmaceutical Microbiology 4 Anti-Inflammatory & Anti- Allergy Agents in Medicinal
More informationResearch Strategies, Trends, Opportunities in Pediatric Infectious Disease. Dr. Jaime C. Montoya, MD, MSc, PhD, CESO III Executive Director
Research Strategies, Trends, Opportunities in Pediatric Infectious Disease Dr. Jaime C. Montoya, MD, MSc, PhD, CESO III Executive Director Current state of S and T in the country Current state of research
More informationThe Power to Cure: Therapeutic Innovation in Academia
The Power to Cure: Therapeutic Innovation in Academia Leslie Molony, Ph.D. November 7, 2011 Sanford-Burnham Medical Research Institute: a Non Profit Basic Research Institute Santa Barbara Est. 2006 La
More informationin Combating Malaria Manos Perros Pfizer Global Research & Development Musée de la Croix-Rouge, Geneva November 12, 2009
Role of the Private Sector in Combating Malaria Manos Perros Pfizer Global Research & Development Musée de la Croix-Rouge, Geneva November 12, 2009 Drug Development and the Evolving R&D Ecosystem Research
More informationEuropean Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic
More informationA GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA
A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA Découpe 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s Patient centered, translational technology
More informationTranslational Research through Public-Private Partnerships. 65 th Annual Bohan Lecture. Scott J. Weir, PharmD, PhD 08 October 2011
Translational Research through Public-Private Partnerships 65 th Annual Bohan Lecture Scott J. Weir, PharmD, PhD 08 October 2011 Drug Focused Translational Research Translational Research Defined by the
More informationWelcome to 5 th Munich Biomarker Conference
Clinical Practice and Targeted Therapies in Personalized Medicine Welcome to 5 th Munich Biomarker Conference December 1 st 2 nd, 2015 RAMADA Hotel & Conference Center München Messe We thank our sponsors
More informationA unique Collaborative Model for the Discovery of New Therapeutic Approaches
A unique Collaborative Model for the Discovery of New Therapeutic Approaches THE INNOVATION GAP OPEN INNOVATION TO ADDRESS THE LACK OF PRODUCTIVITY OF BIOPHARMACEUTICAL RESEARCH A PRE-COMPETITIVE PHARMA
More informationAssociate Dean for Research Florida Hospital Chair in cardiovascular Sciences
Associate Dean for Research Florida Hospital Chair in cardiovascular Sciences Goals 1.To have a robust, multi-disciplinary research program in major areas of biomedical research and to be able to compete
More informationThe Role of Public-Private Partnerships & Evidence Generation
The Role of Public-Private Partnerships & Evidence Generation Christina Donatti LLB, BSc, MSc, PsyD IMI Lead, RWE EMEA Strategic Organisation. Janssen Cilag Janssen is proud to feature artwork created
More informationUNLEASH THE POWER OF PRECISION MEDICINE
FROM BENCH TO BEDSIDE UNLEASH THE POWER OF PRECISION MEDICINE DCB, pioneer in biotech. Your partner in drug discovery. www.dcb.org.tw The Center for Biotechnology With over 400 dedicated researchers and
More informationNIHR Cambridge Clinical Research Facility
NIHR Cambridge Clinical Research Facility National Institute for Health Research The perfect environment for experimental medicine studies and early phase clinical trials for Life Sciences, Biotech and
More informationFuture Science Group VISION IN STM PUBLISHING [ BARBARA VALCELLI / ACCUCOMS
Future Science Group VISION IN STM PUBLISHING [ BARBARA VALCELLI / ACCUCOMS BARBARA@ACCUCOMS.COM Publisher of journals, ebooks and ecommunities Introducing Future Science Group About Future Science Group
More informationPIONEERING WORLD-CLASS DRUG DISCOVERY IN AFRICA
PIONEERING WORLD-CLASS DRUG DISCOVERY IN AFRICA MISSION & VISION Prof. Kelly Chibale H3D Director Vision To be the leading organisation for integrated drug discovery and development on the African continent.
More informationNATIONAL INSTITUTES OF HEALTH
NATIONAL INSTITUTES OF HEALTH (dollars in millions) 2011 2012 2013 2013 +/- 2012 Institutes National Cancer Institute... 5,050 5,066 5,069 +3 National Heart, Lung and Blood Institute... 3,065 3,075 3,076
More informationHorizon 2020 Health Summit-IIS La Fe. Valencia, 12 de diciembre de 2017
Horizon 2020 Health Summit-IIS La Fe Valencia, 12 de diciembre de 2017 2 History 3 AsphaTeam +75 members Consultants with Life Science Background 20 team members with PhD High knowhow in drug development
More informationEXECUTIVE SUMMARY EXECUTIVE SUMMARY. Global funding for neglected disease R&D increased for the first time since The survey.
The survey Each year since 2007, the G-FINDER project has provided policy-makers, donors, researchers and industry with a comprehensive analysis of global investment into research and development (R&D)
More informationDialogue 1: Partnerships in support of strengthening health systems: Building resilience to pandemics 1
ECONOMIC AND SOCIAL COUNCIL PARTNERSHIPS FORUM Dialogue 1: Partnerships in support of strengthening health systems: Building resilience to pandemics 1 Introduction 28 May 2015, 11:00 a.m. 1:00 p.m. UN
More informationMarket Research at the NCBC Library
Market Research at the NCBC Library North Carolina Biotechnology Center Library 15 T.W. Alexander Drive, Research Triangle Park Phone: 919-549-8880 E-mail: library@ncbiotech.org The reports in this list
More informationHannover, your first foothold for business expansion into Europe
Hannover, your first foothold for business expansion into Europe Hannover Clinical Trial Center & hannoverimpuls Support for entering the health care market 1 The Hannover Region features all important
More informationNational Health Research Institutes
National Health Research Institutes October 2008 History The founding of the National Health Research Institutes (NHRI) was first proposed in 1988 by members of Academia Sinica. In 1994 a preparatory committee
More informationPersonalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationChanging the Practice of Medicine. The Novartis Institutes for BioMedical Research
Changing the Practice of Medicine The Novartis Institutes for BioMedical Research 2 Changing the Practice of Medicine Welcome to the Novartis Institutes for BioMedical Research The Novartis Institutes
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More informationFocus on Health Research
Sharing Best Practices in R&D Statistics: Focus on Health Research Eric Buehrens Executive Vice President and Chief Operating Officer, Beth Israel Deaconess Medical Center, Boston 28 June, 2010 Contents
More informationTHE SATVI LAB IN TB VACCINE RESEARCH. Vaccines to stop TB
THE SATVI LAB IN TB VACCINE RESEARCH Vaccines to stop TB The Liquid Nitrogen Container is state-of-the-art laboratory equipment that plays a critical role in our TB vaccine studies. Each container can
More informationRare Diseases: Challenges and Opportunities NIH Perspective
Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes
More informationINTERNATIONAL COLLABORATION. S. Sinha Adviser Department of Biotechnology Ministry of Science & Technology Government of India
INTERNATIONAL COLLABORATION S. Sinha Adviser Department of Biotechnology Ministry of Science & Technology Government of India INDIA S ASSETS Strong pool of scientists and engineers >300,000 institutions
More informationSupplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/6/242/242cm6/dc1 Supplementary Materials for Sandbox: Building and Sharing Resources This PDF file includes: Mark David Lim E-mail: mlim@fastercures.org
More informationEXPERT COLLECTION. Explore our leading medical review series
EXPERT COLLECTION Explore our leading medical review series Introducing the EXPERT COLLECTION The Taylor & Francis Expert Collection is the world s largest series of review journals in research, development,
More informationFrom Bench To Clinic : a personal journey Career Research Advancement Focused Training
From Bench To Clinic : a personal journey Career Research Advancement Focused Training February 13, 2018 Irina Tcherepanova Ph.D. Vice President of Translational Medicine Argos Therapeutics Inc. FDA view
More informationEarly Patient Studies in Evolution. John Horkulak Executive Director, Eurasian External Study Operations Feb 23, 2015
Early Patient Studies in Evolution John Horkulak Executive Director, Eurasian External Study Operations Feb 23, 2015 Questions How are early phase studies evolving and why the push for studying patients
More information7 Sexual Health.
RESE ARCH & DEVELOPMENT 22 Highlights Signed an agreement with Medicines for Malaria Venture (MMV) to provide MMV with access to the Pfizer library of novel chemical entities to screen for compounds that
More informationUniversity of California Center for Accelerated Innovation
University of California Center for Accelerated Innovation MICHAEL PALAZZOLO April 6, 2015 Outline CAI overview and introduction RFA and important dates Selection process Pre-application Finding help 2
More informationSession 1: Nanotechnologies today and tomorrow. Health applications of nanoscience and nanotechnologies
EMRC Session 1: Nanotechnologies today and tomorrow Health applications of nanoscience and nanotechnologies Carole Moquin-Pattey, PharmD, PhD Head of the European Medical Research Councils (EMRC) 25-26
More informationSustainable Health Care Systems: Research and Innovation
Backgroundpaper B7-Communiqué Sustainable Health Care Systems: Research and Innovation Version II BDI, BUSINESSEUROPE Canadian Chamber of Commerce CBI CONFIDUSTRIA Keidanren MEDEF US Chamber of Commerce
More informationEUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008
Work plan for 2008 1 Vision In 10 years nanomedicinebased products will lead to breakthroughs in the treatment of diseases such as cardiovascular disease, cancer, CNS diseases and diabetes. 2 The ETP is
More informationThe New Diagnostics WG and The Global Plan to Stop TB
The New Diagnostics WG and The Global Plan to Stop TB 2011-2015 Working Group on New Diagnostics Annual Meeting 11 th November 2010, Berlin Christian Lienhardt Stop TB Partnership Geneva Aims of this presentation
More informationHESI VALUE: Translational Safety Biomarker Assessment of Neurotoxicity Proposal
HESI VALUE: Translational Safety Biomarker Assessment of Neurotoxicity Proposal Jesse L. Goodman, MD, MPH US Food and Drug Administration Emerging Issues Session HESI Annual Meeting 12 June 2012 Prague,
More information"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia
"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS
More informationEducation Critical to Stem Cell Therapy Pipeline
June 2016 Education Critical to Stem Cell Therapy Pipeline Don L. Gibbons Senior Science and Education Communication Officer ABOUT California Institute for Regenerative Medicine (CIRM) CIRM is California
More informationAbout the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
More informationSMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
More informationBMBH BioMaterialBank Heidelberg
BMBH BioMaterialBank Heidelberg NCT-Tissue Bank The Nucleus of BMBH Aims Central and comprehensive tissue bank structure Research not collective-oriented: Making research possible Comprehensive ethical/legal
More informationORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS
ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS 2018-2024 ORACLE 2.0: Leading Globally, from Innovation to Impact P1 P2 NOTE FROM OUR LEADERS NOTE FROM VP RESEARCH,
More informationGHIT の活動から新薬開発へのファンディングを考える. BT Slingsby, CEO, GHIT Fund
GHIT の活動から新薬開発へのファンディングを考える BT Slingsby, CEO, GHIT Fund Anti-Infectives Over 100 Years Development of antibacterial agents in Japan 八木澤守正 : 抗菌薬を概観する : 過去, 現在, そしてこれから 日化療会誌 2016 60: 149-167 舘田一博 : 抗菌薬開発停滞の打破へ向けて
More informationSMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project? IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
More informationSingHealth and A*STAR to advance medical research in diabetes; immunotherapy and drug development; and precision medicine
MEDIA RELEASE SingHealth and A*STAR to advance medical research in diabetes; immunotherapy and drug development; and precision medicine Strategic partnership sees Singapore s largest public healthcare
More information5-Year Evaluation of the Global Fund Design, Methods, and Comments
5-Year Evaluation of the Global Fund Design, Methods, and Comments Presentation at IOM Martin Vaessen ICF Macro January 7, 2010 1 Evaluation Design Study Area 1: Global Fund Organizational Efficiency and
More informationthe clinical research institute at RAMBAM
the clinical research institute at RAMBAM A commitment to science. A commitment to life. One of the greatest challenges facing today s leading healthcare institutions is the identification of the clinical
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationConsortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts Martha A. Brumfield, PhD President & CEO Agenda C-Path Model for Collaboration
More informationNew Paradigms in Drug Discovery: How Genomic Data are Being Used to Revolutionize the Drug Discovery and Development Process A Workshop
Board on Health Sciences Policy Roundtable on Translating Genomic-Based Research for Health New Paradigms in Drug Discovery: How Genomic Data are Being Used to Revolutionize the Drug Discovery and Development
More informationMissouri Regional Life Sciences Summit March 9, 2010 The Institute for Advancing Medical Innovation Stepping into the future of drug discovery, delivery and biomedical engineering G. Sitta Sittampalam,
More informationCritical Path to TB Drug Regimens (CPTR)
Critical Path to TB Drug Regimens (CPTR) Why do we need a CPTR initiative? We finally have a pipeline of TB drug candidates Today, we test drugs same way we did 20 years ago Need better tests for drug
More informationMRC Translational Funding
MRC Translational Funding Dr Jo Latimer- 29 February 2016 Medical Research Council MRC: Leading & Partnering Research Dedicated to improving human health through the best scientific research. Established
More informationPan African Clinical Trials Registry (PACTR) Amber Abrams, Project Manager South African Cochrane Centre
Pan African Clinical Trials Registry (PACTR) Amber Abrams, Project Manager South African Cochrane Centre Acknowledgements The European and Developing Countries Clinical Trials Partnership (EDCTP) Trial
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationWorld Congress on Infectious Diseases & Vaccines About the Conference: Aim Target Audience Conference Highlights
World Congress on Infectious Diseases & Vaccines About the Conference: Gavin Conferences invites participants from all over the world to attend World Congress on Infectious Diseases & Vaccines. Infectious
More informationThe European Medicines Agency: A well-established Agency of the EU protecting human and animal health for all EU citizens
14 July 2016 EMA/457243/2016 The European Medicines Agency: A well-established Agency of the EU protecting human and animal health for all EU citizens 1. Who we are The European Medicines Agency (EMA)
More informationThe Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More informationWITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT
WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges
More information